Sugi Predict

Sugi Predict / Compounds / SCHEMBL855255

SCHEMBL855255

SCHEMBL855255

CC(C)(C)OC(=O)C(N)c1ccc(CN)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.41
▸ NR1H2 P55055 1/20 0.40
▸ CYP3A4 P08684 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ SLC7A5 Q01650 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ PMP22 Q01453 1/20 0.38
▸ NLRP3 Q96P20 1/20 0.38
▸ TPSAB1 Q15661 4/20 0.36
▸ PLG P00747 3/20 0.36
▸ PRSS1 P07477 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ANPEP P15144 1/20 0.36
▸ ERAP2 Q6P179 1/20 0.36
▸ KLK1 P06870 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL23885016 0.98 LOXL2 (0.40) LOXL2NR1H2CYP3A4CYP1A2CYP2D6
SCHEMBL27846898 0.88 TAAR1 (0.39) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL3643384 0.87 PPARG (0.41) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27364974 0.86 CYP3A4 (0.41) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL855512 0.85 SLC7A5 (0.44) LOXL2NR1H2CYP3A4CYP2D6NFKB1
SCHEMBL5212646 0.84 ANPEP (0.43) NR1H2CYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL8127986 0.84 CYP3A4 (0.38) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL28162095 0.82 FFAR1 (0.45) NR1H2LMNA
SCHEMBL27572794 0.82 CYP4F2 (0.46) SLC7A5LMNASMN1; SMN2
SCHEMBL9995953 0.81 MIF (0.40) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116940562-A Acetamido-phenylbenzamide derivatives and methods of use thereof 希华医药有限公司 2023-10-24 — — CN disclosed
EP-4225745-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Athenex, Inc. (US) 2023-08-16 — — EP disclosed
WO-2022076662-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ATHENEX, INC. (US) 2022-04-14 — — WO disclosed
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Health Hope Pharma Limited (HK) 2022-04-07 — — US disclosed
US-8680091-B2 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2014-03-25 — — US disclosed
US-8563714-B2 Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists ACTELION PHARMACEUTICALS LTD. (CH) 2013-10-22 — — US disclosed
CN-101258131-B As 5-HT2c6-aralkylamino-2 receptor agonists LILLY CO ELI 2013-07-24 — — CN disclosed
EP-2432760-B1 BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-07-17 — — EP disclosed
EP-1924561-B1 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2012-11-14 — — EP disclosed
US-20120115841-A1 BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 — — US disclosed
US-20030083344-A1 Tryptase inhibitors ALTANA PHARMA AG (DE) 2003-05-01 — — US disclosed
US-6489327-B1 TREATING A DISEASE SUSCEPTIBLE TO TRYPTASE INHIBITION SUCH AS ASTHMA, INFLAMMATORY BOWEL DISEASE, PSORIASIS OR RHINITIS MAX-PLANCK-GESELLSCHAFT ZUR FORDRUNGDER WISENSCHAFTEN, E.V. (DE) 2002-12-03 — — US disclosed
EP-1244643-A1 TRYPTASE INHIBITORS ALTANA Pharma AG (DE) 2002-10-02 — — EP disclosed
WO-2002066420-A2 TRYPTASE INHIBITORS ALTANA PHARMA AG (DE) 2002-08-29 — — WO disclosed
WO-2002066430-A1 TRYPTASE INHIBITORS ALTANA PHARMA AG (DE) 2002-08-29 — — WO disclosed
EP-1216236-A1 TRYPTASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2002-06-26 — — EP disclosed
EP-1208089-A2 DIAZOCIN-DIONE DERIVATIVES AND THEIR USE AS TRYPTASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2002-05-29 — — EP disclosed
WO-2001046168-A1 TRYPTASE INHIBITORS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2001-06-28 — — WO disclosed
WO-2001019809-A1 TRYPTASE INHIBITORS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2001-03-22 — — WO disclosed
WO-2001010848-A2 DIAZOCIN-DIONE DERIVATIVES AND THEIR USE S TRYPTASE INHIBITORS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2001-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115841-A1 BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS FPR1, FPR2, FPR3 LOXL2 86/4885NR1H2 10/4885CYP3A4 1653/4885
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ABCB1, ABCC1, UGT2B7 LOXL2 4140/4885NR1H2 1124/4885CYP3A4 11/4885
US-20030083344-A1 Tryptase inhibitors TPSAB1, TPSB2, TPSG1 LOXL2 1231/4885NR1H2 4185/4885CYP3A4 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.